Eupraxia Pharmaceuticals News - August 10, 2026
🔴 Eupraxia Pharmaceuticals is trading 5.17% down today in pre-market — No confirmed company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 5.17% down at $6.42 in pre-market after declining from the August 7 close of $6.77; no confirmed company-specific...
🟢 Eupraxia Pharmaceuticals is trading 9.31% up in pre-market ahead of Q2 2026 earnings release
Eupraxia Pharmaceuticals is trading sharply higher at $7.40, up +9.31%, in pre-market on August 10, 2026, as investors may be positioning ahead of its Q2 2026...
Eupraxia Pharmaceuticals Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Eupraxia Pharmaceuticals to report a consensus loss per share of $0.25 on zero revenue, with the current stock...